Last reviewed · How we verify
EPOETINE ALPHA
Epoetin alfa is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells.
Epoetin alfa is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells. Used for Anemia associated with chronic kidney disease, Anemia in patients with cancer receiving chemotherapy, Anemia in patients with HIV infection.
At a glance
| Generic name | EPOETINE ALPHA |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Erythropoiesis-stimulating agent (ESA) |
| Target | Erythropoietin receptor (EPOR) |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | Phase 3 |
Mechanism of action
Epoetin alfa is a glycoprotein that mimics endogenous erythropoietin, a hormone produced primarily by the kidneys that regulates red blood cell formation. By binding to erythropoietin receptors on erythroid progenitor cells in the bone marrow, it promotes their proliferation, differentiation, and maturation into mature red blood cells. This increases hemoglobin levels and oxygen-carrying capacity of the blood.
Approved indications
- Anemia associated with chronic kidney disease
- Anemia in patients with cancer receiving chemotherapy
- Anemia in patients with HIV infection
- Perioperative anemia management
Common side effects
- Hypertension
- Headache
- Thrombotic events (venous thromboembolism, stroke)
- Injection site reactions
- Flu-like symptoms
- Bone pain
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |